< Back to previous page
Researcher
Christophe Pannecouque
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Jul 2002 → Today
Projects
1 - 3 of 3
- An automated platform for multiparameter data collection on live pathogens of higher or unknown biosafety risk.From26 Jun 2014 → 31 Dec 2018Funding: Hercules - Large scale research infrastructure
- Mechanistic study on virus entry and replication. A fundamental approach to the development of new and specific antiviral chemotherapeutics.From1 Jan 2010 → 31 Dec 2014Funding: BOF - Concerted Research Project from 1994
- Identification of biomarkers and new therapeutic targets in HTLV-1-associated pathologies.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project
Publications
1 - 10 of 399
- Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles.(2024)
Authors: Christophe Pannecouque
Pages: e29502 - Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2-d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants.(2024)
Authors: Erik De Clercq, Christophe Pannecouque
Pages: 1257 - 1282 - In situ click chemistry-based discovery of 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs by exploiting the tolerant region I in binding pocket(2023)
Authors: Erik De Clercq, Christophe Pannecouque
- Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators(2023)
Authors: Erik De Clercq, Christophe Pannecouque
Pages: 16303 - 16329 - A new alkaloid from Pancratium maritimum - Structure elucidation using computer-assisted structure elucidation (CASE) and evaluation of cytotoxicity and anti-SARS-CoV-2 activity(2023)
Authors: Steven De Jonghe, Johan Neyts, Christophe Pannecouque
Pages: 1 - 7 - Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility(2023)
Authors: Christophe Pannecouque, Erik De Clercq
Pages: 4906 - 4917 - 4-Phenylcoumarin derivatives as new HIV-1 NNRTIs: Design, synthesis, biological activities, and computational studies(2023)
Authors: Christophe Pannecouque
- Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety(2023)
Authors: Christophe Pannecouque
- 5-Cyano substituted diarylpyridines as potent HIV-1 NNRTIs: Rational design, synthesis, and activity evaluation(2023)
Authors: Erik De Clercq, Christophe Pannecouque
- Improving the anti-HIV-1 activity and solubility of poorly water-soluble DAPYs by heteroaromatic replacement strategy: From naphthalene-DAPYs to quinoline-DAPYs(2023)
Authors: Christophe Pannecouque, Erik De Clercq
Patents
1 - 7 of 7
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral activity of novel bicyclic heterocycles (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION (Inventor)